Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 10 (Search time: 0.006 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2018ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cellsEadie, L.; Dang, P.; Goyne, J.; Hughes, T.; White, D.
2018Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionMcClure, B.; Heatley, S.; Kok, C.; Sadras, T.; An, J.; Hughes, T.; Lock, R.; Yeung, D.; Sutton, R.; White, D.
2018Molecular monitoring in CML: How deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.
2018Molecular monitoring in CML: how deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.
2018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsRoss, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
2018A dual role for the N-terminal domain of the IL-3 receptor in cell signallingBroughton, S.; Hercus, T.; Nero, T.; Kan, W.; Barry, E.; Dottore, M.; Cheung Tung Shing, K.; Morton, C.; Dhagat, U.; Hardy, M.; Wilson, N.; Downton, M.; Schieber, C.; Hughes, T.; Lopez, A.; Parker, M.
2018Role of the β common (βc) family of cytokines in health and diseaseHercus, T.; Kan, W.; Broughton, S.; Tvorogov, D.; Ramshaw, H.; Sandow, J.; Nero, T.; Dhagat, U.; Thompson, E.; Tung Shing, K.; McKenzie, D.; Wilson, N.; Owczarek, C.; Vairo, G.; Nash, A.; Tergaonkar, V.; Hughes, T.; Ekert, P.; Samuel, M.; Bonder, C.; et al.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2018Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell linesLu, L.; Kok, C.; Saunders, V.; Wang, J.; McLean, J.; Hughes, T.; White, D.; White, D.
2018Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosisTvorogov, D.; Thomas, D.; Liau, N.; Dottore, M.; Barry, E.; Lathi, M.; Kan, W.; Hercus, T.; Stomski, F.; Hughes, T.; Tergaonkar, V.; Parker, M.; Ross, D.; Majeti, R.; Babon, J.; Lopez, A.